Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Leases: 2009-2024

Historic Current Leases for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $3.2 million.

  • Ironwood Pharmaceuticals' Current Leases rose 1.99% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 1.99%. This contributed to the annual value of $3.2 million for FY2024, which is 2.02% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Current Leases of $3.2 million as of FY2024, which was up 2.02% from $3.1 million recorded in FY2023.
  • Ironwood Pharmaceuticals' Current Leases' 5-year high stood at $3.2 million during FY2024, with a 5-year trough of $3.1 million in FY2022.
  • In the last 3 years, Ironwood Pharmaceuticals' Current Leases had a median value of $3.1 million in 2023 and averaged $3.1 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Current Leases soared by 172.95% in 2020, and later declined by 1.98% in 2022.
  • Over the past 5 years, Ironwood Pharmaceuticals' Current Leases (Yearly) stood at $3.1 million in 2020, then decreased by 0.03% to $3.1 million in 2021, then dropped by 1.98% to $3.1 million in 2022, then increased by 1.99% to $3.1 million in 2023, then rose by 2.02% to $3.2 million in 2024.